The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gurmikov B.N.

Vishnevsky National Medical Research Center of Surgery

Kovalenko I.A.

Central State Medical Academy of Department for Presidential Affairs of the Russian Federation

Paichadze A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Marinova L.A.

Vishnevsky National Medical Research Center of Surgery

Gritskevich A.A.

V.A. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of Russia;
Peoples’ Friendship University of Russia

Zhao A.V.

Vishnevsky National Medical Research Center of Surgery

Long-term results of surgical treatment for intrahepatic cholangiocarcinoma according to the tumor mutation status

Authors:

Gurmikov B.N., Kovalenko I.A., Paichadze A.A., Marinova L.A., Gritskevich A.A., Zhao A.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2021;10(6): 6‑13

DOI: 10.17116/onkolog2021100616

Read: 932 times

Download PDF (RU)
Contact the author
Table of contents

LONG-TERM RESULTS OF SURGICAL TREATMENT FOR INTRAHEPATIC CHOLANGIOCARCINOMA ACCORDING TO THE TUMOR MUTATION STATUS
LONG-TERM RESULTS OF SURGICAL TREATMENT FOR INTRAHEPATIC CHOLANGIOCARCINOMA ACCORDING TO THE TUMOR MUTATION STATUS

To cite this article:

Gurmikov BN, Kovalenko IA, Paichadze AA, Marinova LA, Gritskevich AA, Zhao AV. Long-term results of surgical treatment for intrahepatic cholangiocarcinoma according to the tumor mutation status. P.A. Herzen Journal of Oncology. 2021;10(6):6‑13. (In Russ.)
https://doi.org/10.17116/onkolog2021100616

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Opti­mized inte­rdisciplinary approach in the treatment of maxi­llary sinus upper wall fractures in children. Russian Bulletin of Otorhinolaryngology. 2024;(5):29-34
Heavy eye syndrome: clinical mani­festations, diagnosis and treatment. Russian Annals of Ophthalmology. 2024;(5):112-117
Inte­rventional radiological and endo­scopic technologies in diagnosis and treatment of chro­nic pancreatitis. Piro­gov Russian Journal of Surgery. 2024;(11):84-93
Giant peri­cranial sinus with exte­nsive occi­pital calvarium defect. Burdenko's Journal of Neurosurgery. 2024;(6):77-87
Surgical treatment of asce­nding aortic dissection after previous thoracic endo­vascular aortic repair and proximal stent-graft indu­ced new entry. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):682-685
Long-term postoperative outcomes after surgical correction of congenital subaortic stenosis. Piro­gov Russian Journal of Surgery. 2024;(12):60-66
Difficulties in surgical treatment of fixed cardiofundal axial esophageal hiatal hernia. Piro­gov Russian Journal of Surgery. 2024;(12):105-108
Clinical case of auri­cular gouty tophi. Russian Bulletin of Otorhinolaryngology. 2024;(6):80-84
Evaluation of the impact of a comprehensive reha­bilitation program on improving nutritional status, psychoemotional signs and adve­rse events in patients with mela­noma after surgical treatment. Piro­gov Russian Journal of Surgery. 2024;(12-2):173-178
Surgical access for thoracic and intrathoracic goiter. Piro­gov Russian Journal of Surgery. 2025;(1):54-61
Abstract:

OBJECTIVE

To evaluate the effect of the most common gene mutations in intrahepatic cholangiocarcinoma on overall and relapse-free survival after surgical treatment in a Russia’s population.

MATERIAL AND METHODS

A molecular genetic study was conducted to examine tumor materials from 33 patients with intrahepatic cholangiocarcinoma after surgical treatment. The incidence of mutations in the KRAS, IDH1/2, NRAS, PIK3CA, MET, BRAF600, EGRF, and ERBB2 genes, as well as the overall and relapse-free survival of patients after surgical treatment were assessed taking into account the mutations identified.

RESULTS

In a Russia’s population, the incidence of different mutations in intrahepatic cholangiocarcinoma was estimated in the genes of KRAS (27%; n=9), IDH1/2 (24%; n=8), NRAS (12%; n=4), PIK3CA (9%; n=3), MET (9%; n=3), BRAF600 (9%; n=3), EGRF (3%; n=1), and ERBB2 (3%; n=1). The mutations of a favorable prognosis may include those in the IDH1/2 genes; at the same time, the mutations in the MET and PIK3CA genes were unfavorable prognostic factors in terms of overall and relapse-free survivals. Discussions are ongoing as to what effect is produced by the KRAS gene mutation on patient survival after surgical treatment. The investigation showed that the KRAS gene mutation had no negative effect on prognosis.

CONCLUSION

The results of surgical treatment are affected by molecular genetic disorders. Molecular genetic tumor profiling can expand an understanding of the mutation status of the tumor and identify potential targets for molecular-oriented therapy.

Keywords:

intrahepatic cholangiocarcinoma
surgical treatment
molecular genetic studies
gene mutations
long-term results
targeted therapy

Authors:

Gurmikov B.N.

Vishnevsky National Medical Research Center of Surgery

Kovalenko I.A.

Central State Medical Academy of Department for Presidential Affairs of the Russian Federation

Paichadze A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Marinova L.A.

Vishnevsky National Medical Research Center of Surgery

Gritskevich A.A.

V.A. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of Russia;
Peoples’ Friendship University of Russia

Zhao A.V.

Vishnevsky National Medical Research Center of Surgery

Received:

02.07.2021

Accepted:

27.07.2021

Close metadata

References:

  1. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472-477.  https://doi.org/10.1016/j.jhep.2003.11.030
  2. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56(4):848-854.  https://doi.org/10.1016/j.jhep.2011.11.015
  3. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25(7):1011-1016. https://doi.org/10.3346/jkms.2010.25.7.1011
  4. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, Vecchia CL. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24(6):1667-1674. https://doi.org/10.1093/annonc/mds652
  5. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173-184.  https://doi.org/10.1002/hep.24351
  6. Ma B, Meng H, Tian Y, Wang Y, Song T, Zhang T, Wu Q, Cui Y, Li H, Zhang W, Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC cancer. 2020;20(1):318.  https://doi.org/10.1186/s12885-020-06804-6]
  7. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011;105(1):131-138. Published online 2011 Jun 14.  https://doi.org/10.1038/bjc.2011.199
  8. Gurmikov BN, Kovalenko YuA, Vishnevsky VA, Chzhao AV. Molecular genetic aspects of intrahepatic cholangiocarcinoma: literature review. Advances in Molecular Oncology. 2019;6(1):37-43. (In Russ.). https://doi.org/10.17650/2313-805X-2019-6-1-37-43
  9. Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules. 2020;25(16):3754. https://doi.org/10.3390/molecules25163754
  10. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov. 2017;7(10):1116-1135. https://doi.org/10.1158/2159-8290.CD-17-0368
  11. Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A, et al. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: A population-based study. J Transl Med. 2016;14(1):292.  https://doi.org/10.1186/s12967-016-1053-z
  12. Palmieri G, Ombra M, Colombino M, Casula M, Sini M, Manca A, Paliogiannis P, Ascierto PA, Cossu A. Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol. 2015;5:183.  https://doi.org/10.3389/fonc.2015.00183
  13. Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: Potential impact of genomic studies on clinical management. Z Gastroenterol. 2017;55(6):575-581.  https://doi.org/10.1055/s-0043-102581
  14. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS One. 2014;9(12):e115383. https://doi.org/10.1371/journal.pone.0115383
  15. Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer. 2014;111(9):1788-1801. https://doi.org/10.1038/bjc.2014.475
  16. Goeppert B, Frauenschuh L, Renner M, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014;27(7):1028-1034. https://doi.org/10.1038/modpathol.2013.206
  17. Bunyatov T, Zhao A, Kovalenko J, Gurmikov B, Vishnevsky V. Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. J Gastrointest Oncol. 2019;10(4):815-820.  https://doi.org/10.21037/jgo.2019.03.05
  18. Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016;22(2):291-300.  https://doi.org/10.1158/1078-0432.CCR-14-3296
  19. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873-886.  https://doi.org/10.1038/nrd3847
  20. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802-804.  https://doi.org/10.1126/science.1846706
  21. Johnson M, Koukoulis G, Kochhar K, Kubo C, Nakamura T, Iyer A. Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection. Cancer Letters. 1995;96(1):37-48.  https://doi.org/10.1016/0304-3835(95)03915-j
  22. Kochhar KS, Johnson ME, Volpert O, Iyer AP. Evidence for autocrine basis of transformation in NIH-3T3 cells transfected with met/HGF receptor gene. Growth Factors. 1995;12(4):303-313.  https://doi.org/10.3109/08977199509028968
  23. Wang SC, Wu YT, Lui TT, Weng SW, You HL, Wei YC, Eng HL, Huang WT. Amplification and overexpression of the MET gene in intrahepatic cholangiocarcinoma correlate with adverse pathological features and worse clinical outcome. Int J Clin Exp Pathol. 2017;10(6):6809-6817. www.ijcep.com/ISSN:1936-2625/IJCEP0043582
  24. Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncology. 2019;10(4):652-662.  https://doi.org/10.21037/jgo.2018.08.18
  25. Barat S, Bozko P, Chen X, Scholta T, Hanert F, Götze J, Malek NP, Wilkens L, Plentz RR. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog. 2016;55(12):2037-2050. https://doi.org/10.1002/mc.22449
  26. King D, Yeomanson D, Bryant HE. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol. 2015;37(4):245-251.  https://doi.org/10.1097/MPH.0000000000000329
  27. Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget. 2014;5(9):2372-2389. https://doi.org/10.18632/oncotarget.1706
  28. Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D’Onofrio M, Iacono C, Scarpa A, Guglielmi A. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. Ann Surg Oncol. 2016;23(5):1699-1707. https://doi.org/10.1245/s10434-015-5046-6
  29. McRee AJ, Sanoff HK, Carlson C, Ivanova A, O’Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Investigational new Drugs. 2015;33(6):1225-1231. https://doi.org/10.1007/s10637-015-0298-3
  30. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res. 2019;25(7):2033-2041. https://doi.org/10.1158/1078-0432.CCR-18-2275
  31. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.  https://doi.org/10.1186/s13045-015-0155-z
  32. Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol. 2012;30(27):e271-273.  https://doi.org/10.1200/JCO.2012.42.3061
  33. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018;36(6):536-542.  https://doi.org/10.1200/JCO.2017.75.3780
  34. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006;12(6):1680-1685. https://doi.org/10.1158/1078-0432.CCR-05-1692
  35. Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol. 2005;131(10):649-652.  https://doi.org/10.1007/s00432-005-0016-1
  36. Chang YT, Chang MC, Huang KW, Tung CC, Hsu C, Wong JM. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. J Gastroenterol Hepatol. 2014;29(5):1119-1125. https://doi.org/10.1111/jgh.12505
  37. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356-365.  https://doi.org/10.1002/path.1779
  38. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418-425.  https://doi.org/10.1038/sj.bjc.6604129
  39. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021-1031.e15.  https://doi.org/10.1053/j.gastro.2011.12.005
  40. Xu S, Guo Y, Zeng Y., Song Z, Zhu X, Fan N, Zhang Z, Ren G, Zang Y, Rao W. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma. BMC cancer. 2021;21(1):152.  https://doi.org/10.1186/s12885-021-07792-x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.